Most People Use MOTS-C Wrong (Add This First)

Mitochondria are the organelles inside your cells that generate most of your body's usable energy, and they do this through a process called oxidative phosphorylation, which is essentially a chain of chemical reactions that converts nutrients into something called ATP, or adenosine triphosphate, which your body uses as its actual energy currency. Everything that requires energy in your body, from muscle contractions to hormone synthesis to cellular repair, runs on ATP, so the efficiency of your mitochondria determines in a very real way how you feel, how you recover, and how your metabolism handles the food you eat.

What MOTS-c Actually Does at the Cellular Level

MOTS-c is something called a mitochondria-derived peptide, which is a small protein fragment encoded not by your nuclear DNA but by the DNA inside your mitochondria themselves, and this distinction matters because it means MOTS-c is part of a signaling system your body evolved specifically to communicate the status of mitochondrial health to the rest of your cells. Research published in *Free Radical Biology and Medicine* shows that MOTS-c improves what scientists call intrinsic mitochondrial bioenergetic health in a way that depends on two key proteins, PGC-1 alpha and AMPK.

AMPK stands for AMP-activated protein kinase, and it functions as something like a metabolic master switch inside cells, because when your cell's energy supply runs low, AMPK activates a cascade of responses that push the cell toward burning fuel more efficiently, increasing fat oxidation, improving insulin sensitivity, and reducing the production of something called reactive oxygen species, or ROS, which are chemically unstable molecules that damage cellular structures including mitochondrial membranes. So MOTS-c, by activating AMPK, does something that is easy to underestimate: it reduces the very thing that causes mitochondrial damage in the first place, and this is why some researchers and clinicians think of it as both a performance compound and a protective one simultaneously.

PGC-1 alpha functions as what scientists call a master regulator of mitochondrial biogenesis, which means it controls how many mitochondria your cells make and how well those mitochondria function, and because MOTS-c works through this pathway it can actually increase the number of functional mitochondria available for energy production over time, not just improve the ones you already have.

The Role of Cardiolipin and Why SS31 Exists

Inside every mitochondrion there are two membranes, an outer membrane and an inner membrane, and the inner membrane is where the electron transport chain actually runs, so its structural integrity is directly tied to how efficiently your mitochondria produce ATP. Embedded in this inner membrane is a specialized phospholipid called cardiolipin, which is unique to mitochondrial membranes and serves several critical roles including anchoring the protein complexes of the electron transport chain in the correct positions.

When cardiolipin is damaged by oxidative stress, which accumulates with age and metabolic dysfunction, the electron transport chain becomes destabilized and electrons begin leaking out of the chain before completing their intended path, and this leakage is a problem for two reasons: it reduces ATP output because those electrons are no longer doing useful work, and it generates more ROS as a byproduct, so damaged mitochondria create a self-amplifying cycle of further damage.

SS31, also known as elamipretide, is a small tetrapeptide that was designed to cross both mitochondrial membranes and bind directly to cardiolipin, and research from Hazel Szeto's lab published in *Protein and Peptide Letters* describes how this binding stabilizes the inner membrane and reduces electron leakage during energy production by somewhere between 40 and 60 percent. This means SS31 does not optimize healthy mitochondria in the way MOTS-c does. Instead it addresses structural damage that has already accumulated, so it functions more like a repair agent than a performance enhancer, which is why the sequence in which you use these compounds matters more than most people realize.

Why NAD+ Depletion Compounds the Problem

NAD+, or nicotinamide adenine dinucleotide, is a molecule that acts as an electron carrier inside the mitochondrial electron transport chain, and without adequate NAD+ the entire oxidative phosphorylation process slows down regardless of how structurally healthy your mitochondria are, because NAD+ carries electrons from the breakdown of glucose and fat to the protein complexes in the inner membrane where ATP is actually synthesized. Research published in *Clinical and Translational Medicine* has documented that NAD+ levels decline with age at a rate of roughly 50 percent every two decades, so a person in their 50s may have circulating NAD+ levels that are a fraction of what they had at 20, and this decline alone can produce significant reductions in energy, recovery capacity, and metabolic efficiency even if mitochondrial structure is otherwise intact.

The enzyme your body uses to synthesize NAD+ is called NAMPT, which stands for nicotinamide phosphoribosyltransferase, and this is relevant to supplementation strategy because when you supplement NAD+ precursors or NAD+ itself over an extended period without breaks, you risk suppressing your body's own NAMPT activity, meaning your natural production capacity may decline as an adaptation to the external supply, so cycling NAD+ supplementation is not optional if you want to preserve your baseline production over the long term.

The Sequencing Debate and Why It Is Not Just Preference

The core disagreement about whether to use MOTS-c first or SS31 first comes down to a question about cause and effect in mitochondrial dysfunction: is your mitochondria not responding to MOTS-c because it has accumulated structural damage that needs repair before optimization signals can work, or is structural damage less of a limiting factor than metabolic inefficiency, and can preventing future ROS production with MOTS-c handle the problem from upstream?

Both positions have mechanistic logic behind them. If you are younger and your mitochondria have not accumulated significant cardiolipin damage, then MOTS-c can improve bioenergetics through AMPK and PGC-1 alpha, reduce ongoing ROS production, and potentially prevent the damage that would eventually require SS31 in the first place. But if you are in your 40s or 50s and have experienced a decade or more of elevated oxidative stress, sedentary periods, poor metabolic health, or even just the normal aging process, then your mitochondrial inner membranes may have enough structural disruption that MOTS-c signals cannot propagate effectively because the downstream machinery is too compromised to respond, and in that case putting SS31 first to restore membrane integrity gives the MOTS-c a functional platform to work with when you add it later.

Research on mitochondrial aging, including a 2023 study in *Human Reproduction* examining oxidative damage in aging ovarian tissue and work published in *Metabolism* on cardiac aging, confirms that oxidative damage to mitochondrial components is a consistent feature of biological aging across multiple tissue types, not an exceptional condition that only affects people with diagnosed metabolic disease, so the assumption that most people over 40 have significant accumulated mitochondrial damage is not unreasonable.

5-Amino-1-MQ and the NAD+ Recycling Problem

5-amino-1-MQ is a small molecule that functions as an inhibitor of an enzyme called NNMT, or nicotinamide N-methyltransferase, and NNMT's job is to methylate and inactivate nicotinamide, which is a precursor to NAD+, so when NNMT is highly active it essentially routes NAD+ precursors away from recycling and into an inactive form that gets excreted. High NNMT activity is associated with obesity and metabolic dysfunction, and by inhibiting it, 5-amino-1-MQ allows more nicotinamide to stay in the recycling pathway, which means the NAD+ your cells produce and consume can be regenerated more efficiently.

Using the mechanical analogy that helps clarify the whole system: SS31 is the technician fixing cracks in the engine block, MOTS-c is the performance upgrade that makes the engine run more powerfully and cleanly, NAD+ is the fuel the engine burns, and 5-amino-1-MQ prevents exhaust leaks that waste fuel before it can do useful work, so the system retains and recycles energy more efficiently at every stage.

The Structural Logic of Each Protocol

The repair-first protocol runs SS31 at one to two milligrams daily for the first four weeks alongside NAD+ supplementation at 100 milligrams three times per week, and the purpose of this phase is to use SS31 to stabilize damaged cardiolipin and restore inner membrane integrity while using NAD+ to ensure the electron transport chain has adequate electron carriers available during the repair period, so you are fixing structure and supplying substrate at the same time. Then in weeks five through twelve you replace SS31 with MOTS-c at ten milligrams split across three injections per week, continuing the NAD+ at the same dose, and now you are activating AMPK and PGC-1 alpha in mitochondria that have been structurally repaired and have adequate NAD+ available, which means the MOTS-c optimization signal has a functional system to work with.

The prevention-first protocol starts immediately with MOTS-c and NAD+ as a foundation, uses MOTS-c's ROS-reducing effects to prevent the accumulation of the damage that would require SS31, and only adds SS31 for a four to eight week window if an assessment at weeks four through eight reveals persistent fatigue, poor recovery, or insufficient metabolic response, because in that case it signals that existing mitochondrial damage is limiting the response to MOTS-c and repair needs to happen even within a prevention-focused framework.

Both protocols require cycling because of the NAMPT suppression issue with NAD+ and because sustained use of any compound that influences mitochondrial signaling will tend to produce adaptive downregulation of sensitivity over time, so the recommended pattern of eight to twelve weeks on NAD+ followed by four to eight weeks off is based on preserving the responsiveness of your natural NAD+ synthesis machinery rather than arbitrary periodization.

What the Research Cannot Guarantee

The mechanisms described here, AMPK activation by MOTS-c, cardiolipin stabilization by SS31, NAD+ electron carrier function, and NNMT inhibition by 5-amino-1-MQ, are each supported by published research, but it is important to understand that the combined protocols described above are not themselves the subject of randomized controlled trials in the doses and sequences described, so the sequencing logic is built on mechanistic reasoning from individual compound studies rather than direct clinical evidence that one sequence produces better outcomes than another in humans. What the research does support is that each of these compounds has documented effects on mitochondrial function through identifiable pathways, and that mitochondrial dysfunction is a real and measurable feature of aging and metabolic disease that responds to intervention.

Sleep, resistance training, adequate dietary protein, and stress management all influence mitochondrial health through the same pathways these peptides target, because exercise activates AMPK directly, sleep drives mitochondrial repair processes, and protein availability supports the synthesis of the enzymes involved in all of these reactions, so the compounds described here are layered on top of those inputs rather than substituting for them.

---

References

1. Gusenbauer M, Haddaway NR. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. Res Synth Methods. 2020. Source
2. Lindsey WT, Olin BR. PubMed searches: overview and strategies for clinicians. Nutr Clin Pract. 2013. Source
3. Pirani C, Camilleri J. Effectiveness of root canal filling materials and techniques for treatment of apical periodontitis: A systematic review. Int Endod J. 2023. Source
4. Tero-Vescan A, Degens H, Matsakas A et al.. Exercise-Induced Muscle-Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging. Pharmaceuticals Basel. 2025. Source
5. Szeto HH. Stealth Peptides Target Cellular Powerhouses to Fight Rare and Common Age-Related Diseases. Protein Pept Lett. 2018. Source
6. Smits MAJ, Schomakers BV, van Weeghel M et al.. Human ovarian aging is characterized by oxidative damage and mitochondrial dysfunction. Hum Reprod. 2023. Source
7. Ye M, Feng S, Xu Z et al.. Aging and metabolism in HFpEF: Pathophysiology and therapeutic implications. Metabolism. 2026. Source
8. Srivastava S. Emerging therapeutic roles for NAD+ metabolism in mitochondrial and age-related disorders. Clin Transl Med. 2016. Source
9. Gudiksen A, Hansen CC, van der Stede T et al.. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free Radic Biol Med. 2026. Source
10. Fasipe B, Li S, Laher I. Exercise and vascular function in sedentary lifestyles in humans. Pflugers Arch. 2023. Source
11. Li N, Xu Y, Chen Q et al.. MOTS-c Protects Against Acetaminophen-induced Liver Injury through the MAPK Signaling Pathway. Protein Pept Lett. 2026. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness